Aperio HALO AP, an advanced AI-powered image management solution developed in conjunction with Indica Labs, provides seamless integration of digital slides and data into an intuitive interface for rapid on-screen review with comprehensive workflows, live conferencing and collaboration.
The Aperio AI Store, exclusively available via Aperio HALO AP, is a scalable analysis platform incorporating powerful analysis applications developed by an ever-expanding number of leading innovation partners, including Deep Bio, Histofy, Indica Labs and Lunit, all seamlessly embedded in a single interface.
“Showcasing Aperio HALO AP and Aperio AI Store at Pathology Visions is not just a product launch but rather marks a major milestone in our goal of Transforming Pathology, Together,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems.
“There are many partnerships and promises in the digital pathology world, which can be overwhelming for users to identify their right path forward."
|Building on our commitment to interoperability, we believe that providing broad access to AI analysis solutions through a single interface not only provides choice but also represents a practical solution to the growing challenge of multiple software systems and viewers.”
“Delivering on our collaboration with Leica Biosystems, we are proud to bring forward the next wave of innovation in digital pathology software,” said Steven Hashagen, CEO of Indica Labs.
“As leaders in computational pathology, we are continually advancing the field, coupling deep expertise with sophisticated artificial intelligence."
"This technology has the potential to not only elevate diagnostic precision and speed but also pave the way for more personalised and effective patient care.”
Pharmaceutical companies needing AI-powered diagnostics can partner with Leica Biosystems to build custom AI applications for the AI Store and accelerate development.
Built for seamless integration within Aperio HALO AP, the Aperio AI Store delivers unmatched interoperability across an end-to-end computational pathology workflow.
This open, flexible platform empowers partners to streamline development, scale algorithms and deliver new AI applications that provide insights beyond the limits of human interpretation.
These unique capabilities further enable the Leica Biosystems network of pharmaceutical partnerships, exemplified by the partnership announced in May with AstraZeneca.